Table 5. Multivariate analysis of clinical factors for patients in the cohort.
| Characteristic | PFS | OS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| First-line EGFR-TKIs | Second-line osimertinib | First-line EGFR-TKIs | Second-line osimertinib | ||||||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||||
| Age: ≤65 vs. >65 y.o. | 0.725 (0.443–1.187) | 0.201 | 0.483 (0.208–1.119) | 0.089 | 0.763 (0.259–2.242) | 0.622 | 0.6517 (0.089–3.001) | 0.462 | |||
| Sex: female vs. male | 0.724 (0.375–1.398) | 0.336 | 0.634 (0.197–2.040) | 0.445 | 0.516 (0.095–2.809) | 0.444 | 1.144 (0.127–10.322) | 0.905 | |||
| Smoking: never vs. current/former | 1.067 (0.539–2.110) | 0.853 | 1.770 (0.507–6.174) | 0.371 | 3.054 (0.511–18.231) | 0.221 | 1961 (0.165–23.246) | 0.593 | |||
| Stage: IB–IIIA vs. IIIB–IV | 2.071 (0.876–4.898) | 0.097 | 1.223 (0.362–4.127) | 0.746 | 1.132 (0.203–6.308) | 0.888 | 1.436 (0.238–8.648) | 0.693 | |||
| PS: 0–1 vs. 2–3 | 1.674 (0.799–3.504) | 0.172 | 2.478 (0.637–9.644) | 0.191 | 0.163 (0.022–1.236) | 0.079 | 3.211 (0.218–47.278) | 0.395 | |||
| Histology: adenocarcinoma vs. non-adeno | 0.916 (0.375–2.239) | 0.848 | 0.528 (0.148–1.886) | 0.325 | – | 0.990 | – | 0.993 | |||
| EGFR status: 19DEL vs. L858R | 1.543 (0.913–2.607) | 0.105 | 1.085 (0.415–2.834) | 0.868 | 1.653 (0.498–5.488) | 0.412 | 0.523 (0.073–3.742) | 0.518 | |||
| Metformin use: yes vs. no | 0.177 (0.098–0.318) | 0.000 | 0.348 (0.135–0.897) | 0.029 | 0.112 (0.023–0.549) | 0.007 | 1.312 (0.200–8.614) | 0.777 | |||
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; HR, hazard ratio; CI, confidence interval; y.o., years old; PS, performance status.